IVF Reads / Chronic Endometritis After Failed IVF Transfers: Test, Treat, Recheck
Chronic Endometritis After Failed IVF Transfers: Test, Treat, Recheck

Chronic endometritis, a symptomless inflammation of the uterine lining diagnosed by counting CD138-positive plasma cells on an endometrial biopsy, is one of the investigations that ESHRE's 2023 good-practice recommendations on recurrent implantation failure say 'can be considered' after repeated failed embryo transfers; it is not a routine test. Oral antibiotics clear the plasma cells in most women (repeat biopsy negative in 89.3% treated versus 12.7% untreated in the only randomised comparison, Song 2021, 132 women), but no randomised trial has shown that this raises live birth. In the Cheng 2022 meta-analysis of nine studies, ongoing pregnancy or live birth at the next cycle was 41.4% when a repeat biopsy was clear and 23.9% when the condition persisted, a difference whose pooled odds ratio (2.90, 95% CI 0.65 to 12.98) was not statistically significant.
- ESHRE good practice recommendations on recurrent implantation failure (Human Reproduction Open 2023): 'Assessment for chronic endometritis (CE) can be considered. If CE is diagnosed, treatment with antibiotics can be considered.' ESHRE names the unstandardised plasma-cell threshold (more than 1 or more than 5 per high-power field) as a reason the reviews conflict.
- Song et al. (Fertility and Sterility 2021, randomised trial, 132 women with CD138-confirmed chronic endometritis): repeat biopsy negative in 89.3% after oral antibiotics versus 12.7% with no treatment; ongoing pregnancy 43.2% versus 25.7% among those who tried to conceive, not statistically significant.
- Cheng et al. (Journal of Assisted Reproduction and Genetics 2022, nine studies): ongoing pregnancy or live birth 41.4% (92 of 222) after cured CE versus 23.9% (17 of 71) with persistent CE, pooled OR 2.90, 95% CI 0.65 to 12.98. Vitagliano et al. (Fertility and Sterility 2018, five studies, 796 women): OR 6.81 for the same comparison, and cured CE matched women who never had CE.
- Kato et al. (Journal of Infection and Chemotherapy 2022, seven studies, 372 treated and 1,024 untreated): antibiotics did not increase live birth (OR 1.13, 95% CI 0.65 to 1.97). Odendaal et al. (Human Reproduction 2026, placebo-controlled trial, 438 women with recurrent miscarriage): 52% versus 50% live birth or ongoing pregnancy.
- How often it is found depends on the definition and the group: 2.8% of 606 asymptomatic women before a first IVF cycle (Kasius 2011); 33.7% of women with repeated implantation failure (Kitaya 2017); 57.5% by histology in 106 women with RIF (Cicinelli 2015); no excess over controls in a 2024 meta-analysis (Ticconi, OR 1.10).
After failed embryo transfers, should you be tested for chronic endometritis?
It is reasonable to ask for it, but it is an option rather than a standard step. ESHRE, the European fertility society, says in its 2023 recommendations on recurrent implantation failure that assessment for chronic endometritis 'can be considered' and that antibiotics 'can be considered' if it is found, placing both among investigations whose benefit is still uncertain. No guideline retrieved for this page recommends testing every IVF patient before a first cycle.
Chronic endometritis is a low-grade inflammation of the uterine lining, identified under the microscope by plasma cells, a type of immune cell, in the lining's supporting tissue. It usually causes no symptoms. How often it is found after failed transfers depends on who is tested and how the laboratory defines it: a 2024 pooled analysis found it in about 6% of women with recurrent implantation failure and about 6% of controls, while two IVF units using their own criteria reported it in a third (Kitaya 2017) and in more than half (Cicinelli 2015) of women referred after repeated failures. Those are not the same thing counted the same way.
If you are reading this after a second or third failed transfer, the pull of a named, treatable cause is obvious, and that is exactly why the figures below deserve a slow read. Chronic endometritis is one item on a longer list; our article on recurrent implantation failure covers the rest of it.
How is it diagnosed, and what will the biopsy report say?
The diagnosis rests on a small sample of the lining, taken in the clinic in a cycle when no embryo is transferred. The pathologist stains it for CD138, a marker carried by plasma cells, and counts them. A hysteroscopy, a camera look inside the uterus, is often done at the same visit and can show changes that suggest the condition (tiny polyps, a swollen or reddened lining). A 2025 pooled analysis of 13 studies put its sensitivity at 84% and specificity at 89% against biopsy, and advised biopsy to confirm because hysteroscopy alone produces false positives.
The report will give a plasma-cell count, and here the field disagrees. Some laboratories call it chronic endometritis at one or more CD138-positive cells per high-power field; others require five or more; others count per ten fields; a 2021 proposal requires both plasma cells and visible changes in the surrounding tissue, after finding that 8 of 26 women (31%) with no fertility history met the one-cell-per-ten-fields definition. ESHRE names this missing standard as a main reason the evidence is hard to read. Ask which cut-off your laboratory used and how many cells were seen, because a count of one and a count of twelve can both come back as 'positive'.
For what the camera part of the visit involves, see hysteroscopy in the infertility work-up.
If the biopsy is positive, what does antibiotic treatment actually do?
Two different questions hide in that one. Does a course of oral antibiotics clear the plasma cells? Usually, yes. Does clearing them lead to more babies? That has not been shown in a controlled trial.
On the first: in the only randomised trial that compared antibiotics with no treatment (132 women, Song 2021), the repeat biopsy was negative in 89.3% of treated women versus 12.7% of untreated women. Which antibiotic, and for how long, is your clinician's decision; no regimen has been shown to be better than another.
On the second: in the same Song trial, ongoing pregnancy among women who then tried to conceive was 43.2% with treatment and 25.7% without, a gap that did not reach statistical significance in a trial of that size. A 2022 meta-analysis of seven studies (372 treated, 1,024 untreated) found no increase in live birth (odds ratio 1.13, 95% CI 0.65 to 1.97). And in recurrent implantation failure specifically, women given antibiotics without a confirmatory repeat biopsy did no better on live birth than women who never had the condition (Vitagliano 2018; Cheng 2022).
Does the test-of-cure biopsy matter?
Yes, on the evidence we have, and it matters more than the prescription. Every pooled analysis finds the same pattern: women whose repeat biopsy is clear do about as well as women who never had the condition, and women whose biopsy still shows plasma cells do worse than both.
In the 2022 meta-analysis this page cited before its rewrite (Cheng et al., nine studies), ongoing pregnancy or live birth at the next cycle was 41.4% (92 of 222) after a clear repeat biopsy and 23.9% (17 of 71) with persistent disease. Read the results rather than the abstract: because one large study pulled the other way, the pooled odds ratio of 2.90 had a confidence interval of 0.65 to 12.98 and was not statistically significant; it became so (OR 6.02) only when that study was removed. A 2018 meta-analysis of five studies (796 women) found the same direction, odds ratio 6.81 for ongoing pregnancy or live birth, cured versus persistent, and no difference between cured women and women without the condition.
There is a catch. Persistent disease may simply mark women who were going to do badly anyway. And the one placebo-controlled trial of an antibiotic for this condition, in recurrent miscarriage rather than failed transfers, found CD138 staining changed as much between two biopsies on placebo as on treatment, so the count may vary from cycle to cycle on its own. A repeat biopsy before the next transfer is reasonable, because the case for treatment rests on it, but a clear result is reassurance rather than a promise.
What if it is still there after treatment?
Clinics usually offer a second course, often with a different antibiotic. In the 2017 Kitaya series, 92.3% of women were clear after the first course and 99.1% after a second; in the 2015 Cicinelli series, 15 of 61 (24.6%) still showed signs of the condition after the first course. Women with persistent disease had lower implantation, clinical pregnancy and ongoing pregnancy rates than women who never had it (Cheng 2022, odds ratios around 0.4), which is why most clinicians treat again rather than transfer into a positive biopsy. No study has answered how many courses are worth taking or whether anything other than antibiotics helps. If a second biopsy is still positive, that is a conversation about the whole plan, not just another prescription.
What does the evidence not establish?
- That testing every IVF patient improves live birth. Before a first cycle, chronic endometritis was found in 2.8% of 606 women with a normal ultrasound, and their live birth rate was no lower (Kasius 2011). A 2026 review of 39 studies concluded routine screening before a first IVF cycle 'cannot currently be recommended'.
- That antibiotics improve live birth. No randomised trial in IVF patients has shown it. The only placebo-controlled trial (438 women with recurrent miscarriage, 27 UK centres, 2026) found 52% live births or ongoing pregnancies with the antibiotic and 50% with placebo.
- Which antibiotic. A 2026 randomised trial of two common regimens in 160 women found cure rates of 84.8% and 77.8%, no significant difference, with more side effects in the two-drug arm; ESHRE notes regimens are not standardised; a 2026 network meta-analysis of 14 studies found no regimen that improved live birth.
- Where the diagnostic line sits. One cell or five, per field or per ten fields, with or without tissue changes: the threshold changes who is 'positive', and no professional body has settled it.
- Whether the condition is more common after failed transfers at all. Pooled estimates range from no excess over controls (6.4% versus 5.8%, Ticconi 2024) to a third or more in single-centre series.
- Quality. The 2026 review graded the certainty of evidence low or very low for every reproductive outcome; nearly all the data are retrospective or uncontrolled.
- Anything specific to India. No ICMR or Indian society guidance on chronic endometritis was retrieved for this page.
What happens next in your cycle?
Expect the sequence to add at least one or two months. The biopsy is taken in a cycle without a transfer; if it is positive, a course of oral antibiotics follows; the repeat biopsy is usually taken in the next cycle; then the transfer is planned. In the Cicinelli series, every woman had her next IVF attempt within six months of treatment.
Treating the lining does nothing about the embryo, the other half of recurrent implantation failure, so ask what else has been checked. Our pieces on what is worth investigating after a failed IVF cycle and on which inflammation tests are worth doing set out the rest of that list. A negative biopsy is useful too: it closes one line of enquiry without antibiotics.
Not sure what your results mean?
Upload your test results and IVY will explain what has been checked, what it shows, and what usually comes next.
Keep reading
18 Sources
- ESHRE Working Group on Recurrent Implantation Failure; Cimadomo D, de los Santos MJ, Griesinger G, et al. ESHRE good practice recommendations on recurrent implantation failure. Hum Reprod Open. 2023;2023(3):hoad023. Section 'Investigating chronic endometritis'. Human Reproduction Open (ESHRE)
- Cheng X, Huang Z, Xiao Z, Bai Y. Does antibiotic therapy for chronic endometritis improve clinical outcomes of patients with recurrent implantation failure in subsequent IVF cycles? A systematic review and meta-analysis. J Assist Reprod Genet. 2022;39(8):1797-1813. Nine observational studies. Results section: cured vs persistent CE, OPR/LBR 41.4% (92/222) vs 23.9% (17/71), OR 2.90, 95% CI 0.65-12.98, P=0.16. Journal of Assisted Reproduction and Genetics
- Vitagliano A, Saccardi C, Noventa M, et al. Effects of chronic endometritis therapy on in vitro fertilization outcome in women with repeated implantation failure: a systematic review and meta-analysis. Fertil Steril. 2018;110(1):103-112.e1. Fertility and Sterility (PubMed)
- Vitagliano A, Lagana AS, De Ziegler D, et al. Chronic endometritis in infertile women: impact of untreated disease, plasma cell count and antibiotic therapy on IVF outcome. A systematic review and meta-analysis. Diagnostics (Basel). 2022;12(9):2250. Diagnostics (PubMed)
- Kato H, Yamagishi Y, Hagihara M, et al. Systematic review and meta-analysis for impacts of oral antibiotic treatment on pregnancy outcomes in chronic endometritis patients. J Infect Chemother. 2022;28(5):610-615. Journal of Infection and Chemotherapy (PubMed)
- Song D, He Y, Wang Y, et al. Impact of antibiotic therapy on the rate of negative test results for chronic endometritis: a prospective randomized control trial. Fertil Steril. 2021;115(6):1549-1556. Fertility and Sterility (PubMed)
- Liu Y, Zhao Z, Jiang X, You X, Qu D. Doxycycline vs levofloxacin combined with tinidazole for treating chronic endometritis: a randomized controlled trial. Am J Obstet Gynecol. 2026;234(1):141-148. American Journal of Obstetrics and Gynecology (PubMed)
- Odendaal J, Black N, Fishwick K, et al. A double-blind multi-centre randomised placebo-controlled trial of doxycycline in women with recurrent miscarriage and chronic endometritis defined by CD138 positive stromal cells. Hum Reprod. 2026;41(10):1661-1671. Human Reproduction (PubMed)
- Cicinelli E, Matteo M, Tinelli R, et al. Prevalence of chronic endometritis in repeated unexplained implantation failure and the IVF success rate after antibiotic therapy. Hum Reprod. 2015;30(2):323-330. Human Reproduction (PubMed)
- Kitaya K, Matsubayashi H, Takaya Y, et al. Live birth rate following oral antibiotic treatment for chronic endometritis in infertile women with repeated implantation failure. Am J Reprod Immunol. 2017;78(5):e12719. American Journal of Reproductive Immunology (PubMed)
- Kasius JC, Fatemi HM, Bourgain C, et al. The impact of chronic endometritis on reproductive outcome. Fertil Steril. 2011;96(6):1451-1456. Fertility and Sterility (PubMed)
- Kong J, Zhao J, Sun X, Sun T, Tang L. The impact of CD138 plasma cell severity on IVF-ET outcomes in women with untreated chronic endometritis: a systematic review and meta-analysis. BMC Pregnancy Childbirth. 2026;26(1):527. BMC Pregnancy and Childbirth (PubMed)
- Mihoci AM, Socolov D, Dumitrescu RD, et al. Chronic endometritis in women undergoing in vitro fertilization: diagnostic roles of hysteroscopy and endometrial biopsy and associations with reproductive outcomes. A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2026;327:115417. European Journal of Obstetrics & Gynecology and Reproductive Biology (PubMed)
- Riemma G, Parry JP, De Franciscis P, et al. Hysteroscopic criteria for the diagnosis of chronic endometritis: a systematic review and diagnostic test accuracy meta-analysis. Am J Obstet Gynecol. 2025;233(1):12-24.e4. American Journal of Obstetrics and Gynecology (PubMed)
- McQueen DB, Maniar KP, Hutchinson A, Confino R, Bernardi L, Pavone ME. Redefining chronic endometritis: the importance of endometrial stromal changes. Fertil Steril. 2021;116(3):855-861. Fertility and Sterility (PubMed)
- Ticconi C, Inversetti A, Marraffa S, et al. Chronic endometritis and recurrent reproductive failure: a systematic review and meta-analysis. Front Immunol. 2024;15:1427454. Frontiers in Immunology (PubMed)
- Bulut H, Yeginaltay T, Tunc M, et al. Chronic endometritis diagnosed using a cut-off of >=5 CD138 plasma cells significantly affects the reproductive outcomes of frozen embryo transfer: a case-control study. J Turk Ger Gynecol Assoc. 2023;24(3):165-171. Journal of the Turkish German Gynecological Association (PubMed)
- Gong Z, Qiu YH, Zhao X, et al. Determining a treatment regimen with optimal pregnancy outcomes in patients with chronic endometritis: a systematic review and network meta-analysis. Health Sci Rep. 2026;9(10):e73324. Health Science Reports (PubMed)
Frequently asked questions
Questions the sections above do not answer.
Does chronic endometritis cause symptoms?
Usually none. ESHRE describes it as occurring in women without clinical signs of infection, and the 678 women in the 2011 Kasius study were all asymptomatic with a normal ultrasound. Some women report irregular bleeding or pelvic discomfort, but these are not reliable signs and their absence does not rule the condition out. The diagnosis is made on a biopsy, not on how you feel.
Can a swab, a blood test or a scan diagnose it instead of a biopsy?
Not at present. ESHRE lists bacterial culture and DNA-based tests (PCR, next-generation sequencing) of endometrial samples as other approaches, and says its recommendation may be revised if DNA-based tests prove clearer, but these still need a sample from inside the uterus and none has replaced the plasma-cell count. Ultrasound does not show it. Hysteroscopy can suggest it but, on its own, over-calls it.
Is chronic endometritis the same as endometriosis?
No, despite the similar names. Chronic endometritis is inflammation within the uterine lining, diagnosed on a biopsy and treated with antibiotics. Endometriosis is lining-like tissue growing outside the uterus, diagnosed by imaging or laparoscopy, and is not treated with antibiotics. See our article on endometriosis and infertility if that is the diagnosis in your file.
Do probiotics, steroids or supplements treat it?
No trial retrieved for this page tested probiotics, omega-3 or other supplements against chronic endometritis. Steroids appear only in a 2026 network meta-analysis as an exploratory signal for clinical pregnancy when added to an antibiotic, with no effect on live birth, and the authors asked for cautious interpretation. The earlier version of this page listed these as treatment options; that was not supported by evidence.
It was found before my first IVF cycle, not after failed transfers. Should it be treated?
The evidence does not show a benefit in that setting. Of 606 women biopsied before a first IVF cycle, the 2.8% with chronic endometritis had no lower live birth rate (Kasius 2011). Two pooled analyses of untreated disease found that mild disease (1 to 4 CD138-positive cells per high-power field) had no association with IVF outcome, while severe disease (5 or more) did (Vitagliano 2022; Kong 2026, frozen transfers). Whether to treat is a judgement for your clinician that should weigh the cell count; it is not automatic.

